2. PI3K/Akt/mTOR NF-κB
  3. Akt NF-κB
  4. 115404-57-4

115404-57-4

Niloticin Chemical Structure

115404-57-4

Chemical Structure

  • Niloticin
  • CAS No: 115404-57-4
    Formula: C30H48O3
    Molecular Weight: 456.70
  • IUPAC Name: (5R,9R,10R,13S,14S,17S)-17-((2S,4R)-4-((S)-3,3-dimethyloxiran-2-yl)-4-hydroxybutan-2-yl)-4,4,10,13,14-pentamethyl-1,2,4,5,6,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one
  • InChIKey: GKQMMZUXYRXFOH-QBLSGNHRSA-N
  • SMILES: C[C@@]1(CC[C@@]2([H])[C@@H](C)C[C@H]([C@@](O3)([H])C3(C)C)O)C([C@]4([H])CC[C@]12C)=CC[C@](C(C)5C)([H])[C@@]4(CCC5=O)C

Biological Activity: Niloticin, tetracyclic triterpenoid compound, is a osteoclastogenesis inhibitor. Niloticin shows anti-viral, antioxidative, and mosquitocidal activities. Niloticin inhibits osteoclastogenesis by blocking RANKL-RANK interaction and suppressing the AKT, MAPK, and NF-κB signaling pathways[1].

Cat. No. Product Name Purity Description
HY-N3188 Niloticin ≥98.0% Niloticin, tetracyclic triterpenoid compound, is a osteoclastogenesis inhibitor. Niloticin shows anti-viral, antioxidative, and mosquitocidal activities. Niloticin inhibits osteoclastogenesis by blocking RANKL-RANK interaction and suppressing the AKT, MAPK, and NF-κB signaling pathways.

References

[1]. Xu H, et al. Niloticin inhibits osteoclastogenesis by blocking RANKL-RANK interaction and suppressing the AKT, MAPK, and NF-κB signaling pathways. Biomed Pharmacother. 2022 May;149:112902. [Content Brief]

Keywords:

Niloticin